Stay updated with breaking news from Nasdaq Phio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phio Pharmaceuticals (NASDAQ:PHIO – Free Report) had its price objective reduced by HC Wainwright from $6.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2023 earnings at ($1.30) EPS, FY2023 earnings at ($6.26) […]
Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 124,600 shares, a growth of 783.7% from the November 30th total of 14,100 shares. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover […]
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination ...
Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 14,700 shares, an increase of 19.5% from the August 15th total of 12,300 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average […]
Trial targeting treatment of metastatic melanoma and other solid tumors...